Introduction: Poor graft function (PrGF) is a serious complication of allogeneic hematopoietic cell transplantation (allo-HCT), and current therapies are only partially effective. Eight published reports on the effect of eltrombopag on PrGF showed encouraging results. This study aimed to assess the safety and efficacy of eltrombopag for the treatment of PrGF after allo-HCT.
Methods: A retrospective study was conducted on 23 patients with PrGF following allo-HCT at the King Hussein Cancer Center (KHCC), Amman, Jordan between January 2013 and December 2023. The patient-, disease-, and transplant-related characteristics were obtained from the KHCC-BMT database.
Results: The median age was 47 years (range, 26-68 years), and 13 patients were female. Fourteen patients received reduced-intensity conditioning, and 14 donors were human-leukocyte antigen (HLA) -identical siblings. Median hemoglobin (Hb) concentration pre-eltrombopag administration was 8.5 g/dL (range: 6-14.2 g/dL), granulocytes 7.1 × 10/L (range: 1.6-85 × 10/L), and platelets 18 × 10/L (range: 6-50 × 10/L). Thirteen patients had platelets < 20 × 10/L, and 15 had reduced megakaryocytes. The median CD34-positive cell dose was 6.10 × 10/kg (range: 2.75-9.78 × 10/kg). Eltrombopag was initiated at a median of 105 day (d) post-transplant (range: 29-800 d). The median weekly dose was 488 mg (range: 350-700 mg), and the median treatment duration was 75 d (range: 5-446 d). In total, 65% of patients (n=15) responded at a median of 30 d (range, 7-122 d). Twelve responders were alive at a median follow-up of 30 months (range: 7.0-122 months) with normal blood counts. The 2-year overall rate was 48% (95% confidence intervals, 27-70%), and seven non-responders died because of relapse. No major adverse events were reported.
Conclusion: Eltrombopag improved peripheral blood counts in patients with PrGF following allo-HCT. Thus, response to eltrombopag was predictable and has a significant effect on survival.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11883521 | PMC |
http://dx.doi.org/10.31547/bct-2024-017 | DOI Listing |
JMIR Med Inform
March 2025
LynxCare Inc, Leuven, Belgium.
Background: Processing data from electronic health records (EHRs) to build research-grade databases is a lengthy and expensive process. Modern arthroplasty practice commonly uses multiple sites of care, including clinics and ambulatory care centers. However, most private data systems prevent obtaining usable insights for clinical practice.
View Article and Find Full Text PDFJ Int Med Res
March 2025
Department of Orthopedics Surgery, Affiliated Hospital of Jiaxing University, Jiaxing, China.
ObjectiveThis study aimed to assess the practicality and optimal approach for inserting an anterior occipital condyle screw, as well as to measure the screw placement characteristics.MethodsA total of 80 normal head and cervical spine computed tomography scans (40 males/40 females) were used to construct three-dimensional models. The average age of the participants was 45.
View Article and Find Full Text PDFPediatr Infect Dis J
March 2025
Department of Pediatrics and Intensive Care Medicine.
Background: To evaluate the disease burden, risk of complications and mortality in children with viral detection during the peri-liver transplant period.
Methods: A retrospective cohort study was conducted between January 2020 and December 2023 at a tertiary university hospital. Children who underwent multiplex polymerase chain reaction testing from 7 days before to 14 days after liver transplantation were included.
Blood
March 2025
Sungkyunkwan university school of medicine, Samsung Medical Center, Seoul, Korea, Republic of.
This study aimed to assess the efficacy and safety of combining cemiplimab, an anti-PD1 antibody, with isatuximab, an anti-CD38 antibody, in relapsed or refractory extranodal NK/T-cell lymphoma (R/R ENKTL). The hypothesis was that CD38 blockade could enhance the antitumor activity of PD1 inhibitors. Eligible patients received cemiplimab (250 mg on days 1 and 15) and isatuximab (10 mg/kg on days 2 and 16) intravenously every four weeks for six cycles.
View Article and Find Full Text PDFPediatr Infect Dis J
March 2025
From the Department of Pediatrics.
Background: Critically ill children are at risk for subtherapeutic antibiotic concentrations. The frequency of target attainment and risk factors for subtherapeutic concentrations of cefepime in children have not been extensively studied.
Methods: We performed an observational study in critically ill children receiving a new prescription of standard dosing of cefepime for suspected sepsis (≥2 systemic inflammatory response syndrome criteria within 48 hours of cefepime start).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!